What is Salutaris?
SalutarisMD operates at the intersection of ophthalmology and precision radiotherapy. The company is the developer of BetaCurve, a patented medical device designed to deliver targeted beta radiation to treat conditions such as polypoidal choroidal vasculopathy (PCV). Unlike traditional anti-VEGF injection therapies that require frequent, recurring clinical visits, the SalutarisMD approach offers a one-time, outpatient intervention. This technological shift aims to democratize access to vision-saving treatments, effectively bypassing the economic and geographic barriers that currently limit the efficacy of standard retinal disease management protocols. By focusing on clinical-stage validation, the firm is positioning itself as a disruptive force in the global ophthalmic market.
How much funding has Salutaris raised?
Salutaris has raised a total of $1.2M across 1 funding round:
Private Equity
$1.2M
Private Equity (2014): $1.2M with participation from Hoya Group
Key Investors in Salutaris
Hoya Group
A global technology company specializing in high-tech medical and optical products, with a strong focus on healthcare innovation and advanced manufacturing.
What's next for Salutaris?
With the recent capital deployment, SalutarisMD is expected to accelerate its clinical trial roadmap and expand its regulatory footprint. The strategic focus will likely shift toward optimizing the commercialization pathway for the BetaCurve platform, ensuring that the device meets the rigorous safety and efficacy standards required for widespread adoption in international healthcare systems. As the company transitions from development to potential market entry, the focus will remain on scaling manufacturing capabilities and establishing partnerships with major retinal care centers. This growth trajectory suggests a long-term objective of establishing a new standard of care that reduces the long-term financial and logistical strain on both patients and healthcare providers, ultimately aiming to preserve vision on a global scale.
See full Salutaris company page
